OSTEOGENESIS IMPERFECTA TREATMENT AS AN ELEMENT OF PREGRAVID PREPARATION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper describes a case of pregnancy in a patient with osteogenesis imperfecta (OI). Both Russian and foreign medicine recognizes this disorder as a contraindication to pregnancy due to the high risk of maternal and fetal complications. The paper gives data on current treatments for OI with drugs that inhibit bone resorption. It is noted that their use in women of childbearing age should be considered as an element of pregravid preparation; even in case of their discontinuation during pregnancy, they contribute to the improvement a perinatal outcome and to the intrauterine consolidation of resulting fractures. This conclusion is based on a previous clinical observation. The safety of using bisphosphonates, teriparatide, denosumab, and strontium ranelate in patients during pregnancy and, possibly, lactation is to be investigated.

Full Text

Restricted Access

About the authors

S. Mravyan

Moscow Regional Research Institute of Obstetrics and Gynecology

Email: 1аkmoniiag@mail.ru
Professor MD

S. Novikova

Moscow Regional Research Institute of Obstetrics and Gynecology

Email: 1аkmoniiag@mail.ru
MD

I. Shuglnln

Moscow Regional Research Institute of Obstetrics and Gynecology

Email: 1аkmoniiag@mail.ru
MD

E. Upryamova

Moscow Regional Research Institute of Obstetrics and Gynecology

Email: 1аkmoniiag@mail.ru

N. Biryukova

Moscow Regional Research Institute of Obstetrics and Gynecology

Email: 1аkmoniiag@mail.ru

I. Bocharova

Moscow Regional Research Institute of Obstetrics and Gynecology

Email: 1аkmoniiag@mail.ru
MD

References

  1. Bregou Bourgeois A., Aubry-Rozier B., Bonafé L. et al. Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives // Swiss. Med. Wkly. - 2016; 146: w14322. doi: 10.4414/smw.2016.14322.
  2. Rauch F., Glorieux F. Osteogenesis imperfect // Lancet. - 2004; 363: 1377-85.
  3. Barnes A., Chang W., Morello R. et al. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfect // N. Engl. J. Med. - 2006; 355: 2757-64.
  4. Forlino A., Marini J. Osteogenesis imperfect // Lancet. - 2016; 387: 165771. doi: 10.1016/S0140-6736(15)00728-X.
  5. Zhao X., Yan S. Recent progress in osteogenesis imperfect // Orthop. Surg. - 2011; 3: 127-30.
  6. Мравян С.Р., Шугинин И.О., Новикова С.В. и др. Несовершенный остеогенез и беременность: проблемы, нарастающие к родам // Альманах клин. мед. 2015; 37: 47-51.
  7. Shapiro J., Sponsellor P. Osteogenesis imperfecta: questions and answers // Curr. Opin. Pediatr. - 2009; 21: 709-16. doi: 10.1097/MOP.0b013e328332c68f.
  8. Rauch F., Travers R., Glorieux F. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy // J. Clin. Endocrinol. Metab. - 2006; 91: 511-6.
  9. Antoniazzi F., Monti E., Venturi G. et al. GH in combination with bisphosphonate treatment in osteogenesis imperfect // Eur. J. Endocrinol. - 2010; 163: 479-87. doi: 10.1530/EJE-10-0208.
  10. Bermüdez-Bejarano E., Serrera-Figallo M., Gutiérrez-Corrales A. et al. Analysis of different therapeutic protocols for osteonecrosis of the jaw associated with oral and intravenous bisphpsphonates // Med. Oral Patol. Oral Cir. Bucal. -2017; 22 (1): 43-57. doi: 10.4317/medoral.21477 http://dx.doi.org/doi: 10.4317/ medoral.21477
  11. Basso F., Soares D., Pansani T. et al. Response of a co-culture model of epithelial cells and gingival fibroblasts to zoledronic acid // Braz. Oral Res. - 2016; 30: e122. doi: 10.1590/1807-3107BOR-2016.vol30.0122.
  12. Bubbear J. Atypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and Prevention // Rambam Maimonides Med. J. - 2016; 7 (4): doi: 10.5041/RMMJ.10259.
  13. Carmel A., Shieh A., Bang H. et al. The 25(OH)D level needed to maintain a favorable bisphosphonate response is >33 ng/ml // Osteoporos Int. - 2012; 23: 2479-87. doi: 10.1007/s00198-011-1868-7.
  14. Di Lieto A., Pollio F., De Falco M. et al. Collagen content and growth factor immunoexpression in uterine lower segment of type IA osteogenesis imperfecta: Relationship with recurrent uterine rupture in pregnancy // Am. J. Obstet. Gynecol. - 2003; 189: 594-600.
  15. Приказ Минздравсоцразвития РФ от 05.12.07 №736 «Перечень медицинских показаний к прерыванию беременности».
  16. Zhao X., Yan S. Recent progress in osteogenesis imperfect // Orthop. Surg. - 2011; 3: 127-30. doi: 10.1111/j.1757-7861.2011.00128.x.
  17. Cozzolino M., Perelli F., Maggio L. et al. Management of osteogenesis imperfecta type I in pregnancy; a review of literature applied to clinical practice // Arch. Gynecol. Obstet. - 2016; 293 (6): 1153-9. doi: 10.1007/s00404-016-4012-2.
  18. Stathopoulos I., Liakou C., Katsalira A. et al. The use of bisphosphonates in women prior to or during pregnancy and lactation // Hormones. - 2011; 10: 280-91.
  19. Levy S., Fayez I., Taguchi N. et al. Pregnancy outcome following in utero exposure to bisphosphonates // Bone. - 2009; 44: 428-30. DOI: 10.1016/j. bone.2008.11.001.
  20. Gatti D., Rossini M., Viapiana O. et al. Teriparatide treatment in adult patients with osteogenesis imperfecta type I // Calcif. Tissue Int. - 2013; 93: 44852. doi: 10.1007/s00223-013-9770-2.
  21. Orwoll E., Shapiro J., Veith S. et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfect // J. Clin. Invest. - 2014; 124: 491-8. doi: 10.1172/JCI71101.
  22. Dobnig H., Stepan J., Burr D. et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treatedwith alendronate // J. Bone Miner. Res. - 2009; 24: 1998-2006. doi: 10.1359/jbmr.090527.
  23. Land C., Rauch F., Travers R. et al. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment // Bone. - 2007; 40: 638-44. doi: 10.1016/j.bone.2006.10.010.
  24. Akiyama T., Dass C., Shinoda Y. et al. PEDF regulates osteoclasts via osteoprotegerin and RANKL // Biochem. Biophys. Res. Commun. - 2009; 391: 789-94. doi: 10.1016/j.bbrc.2009.11.139.
  25. Герштейн Е.С., Тимофеев Ю.С., Зуев А.А. и др. Лиганд-рецепторная система RANK/RANKL/ORG и ее роль при первичных новообразованиях костей (анализ литературы и собственные результаты) // Успехи молекулярной онкологии. - 2015; 3: 51-9. doi: 10.17650/2313-805X-2015-2-3-51-59. ВРАЧ 5'2017
  26. Semler O., Netzer C., Hoyer-Kuhn H. et al. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI // J. Musculoskelet. Neuronal. Interact. - 2012; 12: 183-8.
  27. Hoyer-Kuhn H., Franklin J., Allo G. et al. Safety and efficacy of denosumab in children with osteogenesis imperfecta - a first prospective trial // J. Musculoskelet. Neuronal. Interact. - 2016; 16: 24-32.
  28. Deeks E., Dhillon S. Spotlight on strontium ranelate: in postmenopausal osteoporosis // Drugs Aging. - 2010; 27: 771-3. doi: 10.2165/11206440
  29. Shi C., Hu B., Guo L. et al. Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta // J. Bone Miner. Res. - 2016; 31: 1003-14. doi: 10.1002/jbmr.2770.
  30. Vanleene M., Saldanha Z., Cloyd K. et al. Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties // Blood. - 2011; 117: 1053-60. doi: 10.1182/blood-2010-05-287565.
  31. Horwitz E., Prockop D., Gordon P. et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfect // Blood. - 2001; 97: 1227-31.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies